Risk factors associated with progression of diabetic retinopathy in eyes treated with panretinal photocoagulation

被引:4
作者
Baek, Sung Uk [1 ]
Park, Min Seon [1 ]
Cho, Bum-Joo [1 ]
Park, In Won [1 ]
Kwon, Soonil [1 ]
机构
[1] Hallym Univ, Coll Med, Sacred Heart Hosp, Dept Ophthalmol, 22 Gwanpyeong Ro,170beon Gil, Anyang 14068, South Korea
基金
新加坡国家研究基金会;
关键词
MEAN PLATELET VOLUME; RANIBIZUMAB; METAANALYSIS; SEVERITY; THERAPY; MARKER;
D O I
10.1038/s41598-021-93384-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Uncontrolled diabetes has been associated with progression of diabetic retinopathy (DR) in several studies. Therefore, we aimed to investigate systemic and ophthalmic factors related to worsening of DR even after completion of panretinal photocoagulation (PRP). We retrospectively reviewed DR patients who had completed PRP in at least one eye with a 3-year follow-up. A total of 243 eyes of 243 subjects (mean age 52.6 +/- 11.6 years) were enrolled. Among them, 52 patients (21.4%) showed progression of DR after PRP (progression group), and the other 191 (78.6%) patients had stable DR (non-progression group). The progression group had higher proportion of proliferative DR (P=0.019); lower baseline visual acuity (P<0.001); and higher platelet count (P=0.048), hemoglobin (P=0.044), and hematocrit, (P=0.042) than the non-progression group. In the multivariate logistic regression analysis for progression of DR, baseline visual acuity (HR: 0.053, P<0.001) and platelet count (HR: 1.215, P=0.031) were identified as risk factors for progression. Consequently, we propose that patients with low visual acuity or high platelet count are more likely to have progressive DR despite PRP and require careful observation. Also, the evaluation of hemorheological factors including platelet counts before PRP can be considered useful in predicting the prognosis of DR.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Clinical efficacy and acceptability of panretinal photocoagulation combined with conbercept for patients with proliferative diabetic retinopathy A protocol for systematic review and meta-analysis
    Wang, Liangyu
    Chen, Zhaoli
    Wang, Xiaoxue
    MEDICINE, 2021, 100 (17) : E25611
  • [42] PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial
    Jampol, Lee M.
    Odia, Isoken
    Glassman, Adam R.
    Baker, Carl W.
    Bhorade, Anjali M.
    Han, Dennis P.
    Jaffe, Glenn J.
    Melia, Michele
    Bressler, Neil M.
    Tanna, Angelo P.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (01): : 69 - 78
  • [43] Frequency of diabetic retinopathy and associated risk factors in Khartoum, Sudan: population based study
    Elwali, Einas S.
    Almobarak, Ahmed O.
    Hassan, Mona A.
    Mahmooud, Amir A.
    Awadalla, Heitham
    Ahmed, Mohamed H.
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2017, 10 (06) : 948 - 954
  • [44] Outcomes of Pars Plana Vitrectomy with Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy Without Retinal Detachment: A Seven-Year Retrospective Study
    Patel, Veshesh
    Rohowetz, Landon J.
    Pakravan, Parastou
    Kalavar, Meghana
    Yannuzzi, Nicolas A.
    Sridhar, Jayanth
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 471 - 478
  • [45] Anti-Vascular Endothelial Growth Factor Drugs Compared With Panretinal Photocoagulation for the Treatment of Proliferative Diabetic Retinopathy: A Cost-Effectiveness Analysis
    Walton, Matthew
    Bojke, Laura
    Simmonds, Mark
    Walker, Ruth
    Llewellyn, Alexis
    Fulbright, Helen
    Dias, Sofia
    Stewart, Lesley A.
    Rush, Tom
    Steel, David H.
    Lawrenson, John G.
    Peto, Tunde
    Hodgson, Robert
    VALUE IN HEALTH, 2024, 27 (07) : 907 - 917
  • [46] Proliferative diabetic retinopathy treated with intravitreal ranibizumab and photocoagulation directed at ischemic retinal areas—A randomized study
    Luiza Toscano
    Andre Messias
    Katharina Messias
    Rafaella de Cenço Lopes
    Jefferson A. Santana Ribeiro
    Ingrid U. Scott
    Rodrigo Jorge
    Documenta Ophthalmologica, 2021, 143 : 313 - 322
  • [47] Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study
    Chatziralli, Irini
    Dimitriou, Eleni
    Theodossiadis, George
    Kazantzis, Dimitrios
    Theodossiadis, Panagiotis
    ACTA DIABETOLOGICA, 2020, 57 (10) : 1219 - 1225
  • [48] Effectiveness of Panretinal Photocoagulation Plus Intravitreal Anti-VEGF Treatment Against PRP Alone for Diabetic Retinopathy: A Systematic Review With Meta-Analysis
    Zhang, Wuyue
    Geng, Jinsong
    Sang, Aimin
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [49] Cost-effectiveness of the anti-vascular endothelial growth factor intravitreal injection and panretinal photocoagulation for patients with proliferative diabetic retinopathy in South Korea
    Lee, Hyeon-Jeong
    Cho, Songhee
    Park, Jungeun
    Jin, Yan
    Kim, Hyung Min
    Jee, Donghyun
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [50] Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial
    Antoszyk, Andrew N.
    Glassman, Adam R.
    Beaulieu, Wesley T.
    Jampol, Lee M.
    Jhaveri, Chirag D.
    Punjabi, Omar S.
    Salehi-Had, Hani
    Wells, John A., III
    Maguire, Maureen G.
    Stockdale, Cynthia R.
    Martin, Daniel F.
    Sun, Jennifer K.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (23): : 2383 - 2395